Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

BJUI compass

Showing results (351-360 of 642) with videos related to

Pageof 65
Sort By:
BJUI Compass|April 27, 2022
Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB studyHiroji Uemura, Kazuki Kobayashi, Akira Yokomizo, et al.
BJUI Compass|April 27, 2022
Selective arterial embolization of renal angiomyolipomas: A 10-year experienceGuram Nozadze, Signe Benzon Larsen, Søren Heerwagen, et al.
BJUI Compass|April 27, 2022
Behind the scenesJohn W Davis
BJUI Compass|April 27, 2022
Mr. Roboto (domo arigato, if you like)John W Davis
BJUI Compass|May 2, 2022
Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancerAngelyn Anton, Sruti Pillai, Marie Christine Semira, et al.
BJUI Compass|May 2, 2022
Multiple plaque incisions with or without grafting for Peyronie's diseasePaul K Hegarty, Daniel O Sullivan, Penelope A Hegarty, et al.
BJUI Compass|May 2, 2022
2022 May Editorial: 'The Unfair Reviewer Comments'John W Davis
BJUI Compass|March 14, 2024
Impact of androgen deprivation therapy on cognitive function in men with prostate cancerYutaka Yamamoto, Yasunori Akashi, Keisuke Kiba, et al.
BJUI Compass|February 28, 2022
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinomaElio Adib, Talal El Zarif, Rohit K Jain, et al.
BJUI Compass|April 18, 2024
Thoughts on 'Efficacy of RestoreX after prostatectomy: open-label phase of an RCT'Mustafa Ganijee, Rasi Mizori, Awab Ahmad, et al.
Pageof 65

Showing results (351-360 of 642) with videos related to

Sort By:
Pageof 65
BJUI Compass|April 27, 2022
Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB studyHiroji Uemura, Kazuki Kobayashi, Akira Yokomizo, et al.
BJUI Compass|April 27, 2022
Selective arterial embolization of renal angiomyolipomas: A 10-year experienceGuram Nozadze, Signe Benzon Larsen, Søren Heerwagen, et al.
BJUI Compass|April 27, 2022
Behind the scenesJohn W Davis
BJUI Compass|April 27, 2022
Mr. Roboto (domo arigato, if you like)John W Davis
BJUI Compass|May 2, 2022
Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancerAngelyn Anton, Sruti Pillai, Marie Christine Semira, et al.
BJUI Compass|May 2, 2022
Multiple plaque incisions with or without grafting for Peyronie's diseasePaul K Hegarty, Daniel O Sullivan, Penelope A Hegarty, et al.
BJUI Compass|May 2, 2022
2022 May Editorial: 'The Unfair Reviewer Comments'John W Davis
BJUI Compass|March 14, 2024
Impact of androgen deprivation therapy on cognitive function in men with prostate cancerYutaka Yamamoto, Yasunori Akashi, Keisuke Kiba, et al.
BJUI Compass|February 28, 2022
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinomaElio Adib, Talal El Zarif, Rohit K Jain, et al.
BJUI Compass|April 18, 2024
Thoughts on 'Efficacy of RestoreX after prostatectomy: open-label phase of an RCT'Mustafa Ganijee, Rasi Mizori, Awab Ahmad, et al.
Pageof 65